Search the Newsreel

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

Short interest in Indaptus Therapeutics (NASDAQ:INDP) dramatically decreased by 64.1% in July, totaling 93,141 shares as of July 31st. Despite beating consensus EPS estimates for the quarter, the stock trades near its one-year low, and analyst sentiment remains negative with an average "Sell" rating. …

Danaher Stock: Is Wall Street Bullish or Bearish?

Down day candlestick chart by Bigc Studio via Shutterstock With a market cap of $143.3 billion, Danaher Corporation (DHR) is a leading global life sciences and diagnostics innovator that combines advanced science, technology, and industry-leading businesses to help customers address complex scientific and clinical …

Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Dimensional Fund Advisors LP significantly reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 86.4% in the first quarter, selling over 1.19 million shares and retaining 188,338 shares. Despite this, institutional investors still hold 99.17% of the stock. Adaptive Biotechnologies reported a 21.5% increase …

Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma …

Indaptus Therapeutics Releases Q2 2026 Financial Results

Indaptus Therapeutics (INDP) reported its Q2 2026 financial results, with a basic and diluted EPS of -$0.02, which represents a significant narrowing of losses compared to Q2 2025. The biotechnology company posted a net loss of $1.8 million for the quarter. Analyst consensus for …

Bronstein, Gewirtz & Grossman, LLC Is Investigating AdaptHealth Corp. (AHCO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AdaptHealth Corp. (AHCO) after the company reported significantly lower-than-expected Q2 2026 revenue and adjusted EBITDA, along with a substantial reduction in full-year guidance. The firm encourages investors who purchased AdaptHealth securities to connect with …

Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary

Indaptus Therapeutics, Inc. reported a significant improvement in its financial results for the second quarter of 2026, with a net loss of $(1.79M) and EPS of $(0.02), primarily due to reduced R&D and G&A spending following the wind-down of its Decoy20 Phase 1 study. …

Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise

Indaptus Therapeutics (INDP) significantly reduced its operating expenses and net loss in Q2 2026, bolstering its cash reserves with a $12 million private placement. The company reported an 83% drop in R&D costs and a narrowed net loss of $1.8 million, while it evaluates …

Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2

Indaptus Therapeutics (INDP) significantly reduced its net loss in Q2 2026 to $1.8 million from $5.2 million in the previous year, primarily due to an 83% cut in R&D and a 37% decline in G&A expenses as it halted its Decoy20 clinical program and …

576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP

Wasatch Advisors LP has acquired 576,266 shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $12.4 million, bringing institutional ownership in the company to 99.17%. Despite a reported wider-than-expected quarterly loss, Adaptive Biotechnologies saw a 21.5% year-over-year revenue increase. The stock is trading near its …

Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan

Adaptive Biotechnologies' Chief Commercial Officer, MRD, Susan Bobulsky, sold 3,000 shares of common stock at $25.00 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on December 16, 2025. Following the sale, Bobulsky directly holds 396,989 …

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales

Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than …

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock

Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of …

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …

AdaptHealth Corp. (AHCO) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky, LLP has issued a securities investigation notice for AdaptHealth Corp. (AHCO) after the company reported second-quarter 2026 revenue and earnings significantly below analyst expectations. Shares of AdaptHealth fell as much as 26% following the announcement of a $0.99 GAAP loss per …

AdaptHealth misses Q2 revenue and earnings estimates, shares drop 26%.

AdaptHealth Corp. (AHCO) reported a significant miss on Q2 2026 revenue and earnings estimates, with revenue at $740.3 million against an anticipated $847 million, and a GAAP loss of $0.99 per share compared to an expected loss of $0.15. This poor performance led to …

Kenneth Samet Bought 94% More Shares In AdaptHealth

Independent Director Kenneth Samet recently purchased US$150k worth of AdaptHealth (NASDAQ:AHCO) shares at US$6.38 each, increasing his holding by 94%. This insider buying activity, along with other purchases totaling US$511k over the last year, suggests a bullish sentiment despite the company's recent loss. Insiders …

Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Suzanne Foster Chief Financial Officer - Jason Clemens Full Conference Call Transcript Operator: Good day, everyone, and welcome to today's AdaptHealth Second Quarter 2026 …

AdaptHealth at Canaccord Genuity’s 46th annual growth conference: refocus deepens

AdaptHealth discussed its business transition at Canaccord Genuity's 46th Annual Growth Conference, focusing on organic growth, debt reduction, and core home medical equipment lines after divesting its diabetes business. The company highlighted strong sleep care demand and 16% Q2 2024 revenue growth, despite facing …

AdaptHealth (NASDAQ:AHCO) Trading Up 10.5% on Insider Buying Activity

AdaptHealth (NASDAQ:AHCO) saw its stock price increase by 10.5% due to significant insider buying activity, specifically by Director Kenneth A. Samet, who increased his holdings by 93.7% with a purchase worth nearly $150,000. Analyst sentiment is mixed but leans positive, with seven analysts rating …

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

Key Points Interested in AdaptHealth Corp.? Here are five stocks we like better. AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to simplify the company and focus on sleep, respiratory and home medical …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Adapthealth director Kenneth Samet buys $149,930 in shares

AdaptHealth Corp. director Kenneth Samet recently purchased 23,500 shares of company stock for $149,930, bringing his total holdings to 48,569 shares. This insider purchase occurs while AHCO stock is trading near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company recently …

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Adapthealth director Dale Wolf buys $244,600 in company stock

Dale B. Wolf, a director at AdaptHealth Corp. (NASDAQ:AHCO), recently purchased 40,000 shares of company stock for $244,600 in early August 2026, with prices between $5.83 and $6.37 per share. These insider purchases occurred while AHCO shares traded near their 52-week low, and InvestingPro …

AdaptHealth (NASDAQ:AHCO) Director Purchases $149,930.00 in Stock

AdaptHealth (NASDAQ:AHCO) Director Kenneth Samet recently purchased 23,500 shares for $149,930, increasing his stake by 93.74%. Despite the purchase and analysts' "Moderate Buy" rating with a $10.29 price target, the stock fell 8.3% to $5.22, nearing its one-year low, with trading volume more than …

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Time To Worry? Analysts Just Downgraded Their AdaptHealth Corp. (NASDAQ:AHCO) Outlook

Analysts have significantly downgraded their near-term forecasts for AdaptHealth Corp. (NASDAQ:AHCO), cutting both revenue and earnings per share estimates for 2026. The consensus now projects a substantial revenue reduction and a loss per share, leading to a 35% drop in the consensus price target. …

ADAPTHEALTH CORP. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12

Leerink Partners has reduced its target price for AdaptHealth Corp. (AHCO) shares from $12 to $7. This change reflects an updated outlook from the investment firm regarding the company's valuation. The article, sourced from Reuters, provides this key financial adjustment.

Indaptus Therapeutics (INDP) to Announce Earnings on Monday

Indaptus Therapeutics (INDP) is set to release its Q2 2026 earnings before the market opens on Monday, August 17th, with analysts forecasting a loss of $1.57 per share. The company's earnings call is scheduled for Friday, August 21, 2026, at 9:30 AM ET. Previously, …

Why AdaptHealth Stock Plummeted This Week

Key Points AdaptHealth posted a huge earnings miss in Q2, and sales also came in below expectations. The company also lowered its fiscal performance targets for the year.10 stocks we like better than AdaptHealth › AdaptHealth(NASDAQ: AHCO) stock got crushed this week after the …